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Abstract
Studies in populations of European descent show longer plasma clot lysis times (CLT) in patients with cardiovascular disease
(CVD) than in controls. No data are available on the association between CVD risk factors and fibrinolytic potential in black
Africans, a group undergoing rapid urbanisation with increased CVD prevalence. We investigated associations between
known CVD risk factors and CLT in black Africans and whether CLTs differ between rural and urban participants in light of
differences in CVD risk. Data from 1000 rural and 1000 urban apparently healthy black South Africans (35–60 years) were
cross-sectionally analysed. Increased PAI-1act, BMI, HbA1c, triglycerides, the metabolic syndrome, fibrinogen concentra-
tion, CRP, female sex and positive HIV status were associated with increased CLTs, while habitual alcohol consumption
associated with decreased CLT. No differences in CLT were found between age and smoking categories, contraceptive use
or hyper- and normotensive participants. Urban women had longer CLT than rural women while no differences were
observed for men. CLT was associated with many known CVD risk factors in black Africans. Differences were however
observed, compared to data from populations of European descent available in the literature, suggesting possible ethnic
differences. The effect of urbanisation on CLT is influenced by traditional CVD risk factors and their prevalence in urban and
rural communities.
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Introduction
Cardiovascular disease (CVD) is a global problem and CVD
risk factors and disease rates continue to rise [1]. The development
of CVD may start early in life but the immediate underlying cause
of a CVD event is the occlusion of a critically situated blood vessel
by a blood clot which results in loss of blood flow to vital organs
[2]. Therefore, the optimal breakdown of clots is an important
protective mechanism in CVD [3].
Various proteins are involved in the lysis of blood clots. These
proteins, such as plasminogen activator inhibitor type-1 (PAI-1),
tissue-type plasminogen activator (tPA) and plasminogen can be
measured individually. They then serve as proxy markers for
fibrinolysis. Alternatively one can measure the global ability of
blood or plasma to lyse clots, with the use of global fibrinolytic
assays. These assays give an indication of the speed with which the
body can lyse clots, often reported as lysis time. In recent years a
plasma fibrinolytic potential assay that mimics the physiological
initiation of coagulation by tissue factor and clot breakdown by
tPA from the endothelium was developed [4].
Various studies conducted in populations of European descent
have shown plasma clot lysis times (CLT) to be associated with
CVD. In general, CVD patients had longer CLTs than controls
[5–9], although it was not the case in all studies [10]. CLT has
furthermore been shown to be associated with individual CVD risk
factors such as increased body mass index (BMI), diabetes,
increased total cholesterol, triglycerides and CRP in European
descendant populations [7,8].
No information is available regarding the association of clot
lysis times and CVD risk factors in Africans, an under-studied
population in CVD epidemiology. CVD, which has often been
thought of as a problem of developed countries is now a major
problem of developing countries including South Africa [11,13].
This increase in CVD prevalence is considered to be attributed
to urbanisation of the black South African population due to
decreased physical activity and changes to Westernised lifestyle
and diet. It has furthermore previously been shown that CVD
risk factors and their contribution to CVD risk may differ
between blacks and European descendant populations [11,12].
Two large epidemiological studies in black South Africans have
shown various CVD risk factors to increase with urbanisation.
Vorster [14] reviewed data from the Transition and Health
during Urbanisation in South Africa (THUSA) study and
reported BMI, smoking prevalence in men, total serum
cholesterol levels and blood pressure to increase with urbanisa-
tion. In the Prospective Urban and Rural Epidemiological
(PURE) population Pieters et al. [15] found blood pressure, BMI,
waist circumference, triglyceride concentrations, fasting plasma
glucose, and PAI-1act, all factors associated with CVD, to be
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significantly higher in the urban participants than in the rural
group.
The purpose of this study was therefore to determine whether
urbanisation, with its increased prevalence of CVD risk factors, is
associated with hypofibrinolysis, and secondly to determine the




Participants were recruited to take part in the South African
arm of the international PURE study. This is a large-scale cohort
study that tracks changing lifestyles, risk factors and chronic
disease using periodic standardised data collection in rural and
urban areas of 17 countries in transition over 12 years [16,17].
The data reported here are from the baseline data of just over
2000 randomly selected participants from well-established rural
(living under tribal law) and urban (living in informal and formal
settlements surrounding cities) communities in the North West
Province of South Africa. The sample size was decided upon,
based on power calculations performed on the THUSA results,
which is a cross-sectional epidemiological study, performed on
similar communities in the same province 10 years prior to PURE
[14]. In order to obtain 2000 participants it was decided to
randomly include 6000 households (3000 from rural and urban
respectively) based on previous experience from the THUSA
study. From these 6000 households, 4000 subjects were identified
who fitted the inclusion criteria. Of these 4000, 2792 (rural = 1444,
urban= 1348) agreed to take part in the study, indicated their
availability during the blood collection period and had no plans to
relocate in the foreseeable future. During the 12 week blood
collection period in 2005 blood was finally collected from 1006
rural and 1004 urban participants. Apparently healthy black
South African men and women between the ages of 35 and 60
years were eligible to participate. Use of chronic medication for
non-communicable diseases and/or any self-reported acute illness
were bases for exclusion. The Ethics committee of the North-West
University, South Africa approved this study. The study procedure
was explained to participants in their home language, after which
participants signed informed consent forms and the study
commenced. All data were treated confidentially and all analyses
were performed with coded data.
Blood Collection
Qualified nursing sisters collected fasting blood samples with
minimum stasis from the antecubital veins of participants using
sterile winged infusion sets and syringes between 07:00 and 11:00
on days of data collection. For the analysis of lipids and C-reactive
protein (CRP) in serum, blood was collected in tubes without
anticoagulant. Blood was collected in EDTA tubes for the
determination of glycosylated haemoglobin (HbA1c) and in
fluoride tubes for glucose measurements. For the analysis of
PAI-1act, fibrinogen concentration and plasma fibrinolytic poten-
tial, blood was collected into citrate tubes and kept on ice until
centrifugation. Samples were centrifuged at 20006g for 15
minutes at 10uC within 30 minutes of collection. Aliquots were
frozen on dry ice, stored in the field at 218uC and then after 2–4
days at 282uC until analysis.
Laboratory Analysis
Serum lipids and high-sensitivity CRP were measured using a
Sequential Multiple Analyser Computer (SMAC), using the
KonelabTM autoanalyser (Thermo Fischer Scientific, Vantaa,
Finland). HbA1c was determined with the D-10 Haemoglobin
testing system (Biorad, Hercules, CA, USA). A hexokinase method
using the SynchronHSytem(s) (Beckman Coulter Co., Fullerton,
CA, USA) and reagents was used to measure plasma glucose.
Human Immunodeficiency Virus (HIV) status of participants was
determined according to the South African Department of Health
protocol and UNAIDS/WHO Policy statement on HIV-testing
with the Rapid HIV test, and if positive a Pareeshak test was
performed to confirm the results. Participants received pre-test
counselling and for those who chose to know the results of their
HIV test, post-test counselling was done in privacy. PAI-1act was
measured using an indirect enzymatic method (Spectrolyze PAI-1,
Trinity Biotech, Bray, Ireland). A modified Clauss method
(Multifibrin U-test, Dade Behring, Deerfield, IL, USA) on the
Dade Behring BCS coagulation analyser was used to determine
fibrinogen concentrations. Plasma fibrinolytic potential of tissue
factor induced clots, lysed by exogenous tPA was measured over a
period of 4 weeks with the method of Lisman et al. [5] with slightly
modified tissue factor and tPA concentrations in order to obtain
comparable CLTs of about 60 min (intra-assay CV=3.6%,
between plate CV=4.5%). Final concentrations were tissue factor
(1256diluted; Dade Innovin, Siemens Healthcare Diagnostics
Inc., Marburg, Germany), CaCl2 (17 mmol/l), tPA (100 ng/ml;
Actilyse, Boehringer Ingelheim, Ingelheim, Germany) and phos-
pholipid vesicles (10 mmol/l; Rossix, Mo¨lndal, Sweden). CLT was
defined as the time from the midpoint of clear to maximum
turbidity, which is representative of clot formation, to the midpoint
of maximum turbidity to clear, which represents the lysis of the
clot [5].
Dietary Intake Analysis and Anthropometrical
Measurements
Quantitative Food Frequency questionnaires, designed and
validated for use in this population, were used to determine
habitual alcohol consumption of study participants.
Anthropometrical measurements were taken according to the
International Standards of Anthropometric assessment [Interna-
tional society for the advancement of Kinanthropometry] and
included weight and height as well as waist circumference. The
recommended waist circumference cut-off for central obesity in
Sub-Saharan Africans, which is $94 cm for men and $80 cm for
women [18] were used to define central obesity and used as the
cut-off for Metabolic syndrome criteria. Blood pressure was
measured with subjects sitting relaxed but upright and the right
arm supported at heart level using an automatic digital blood
pressure monitor (Omron HEM-757).
Statistical Analysis
Data were analysed with the computer software package
Statistica (Statsoft Inc., Tulsa, Oklahoma, USA). A p-value of
0.05 or less was regarded as statistically significant. Normally
distributed data are reported as mean (95% confidence interval or
SD). Data that were not normally distributed were log transformed
to improve normality and reported as median (25th –75th
percentile). T-tests for independent samples were used when
comparing parametric data between two groups and analysis of
variance (ANOVA) with Tukey’s Honest Significant Difference
post hoc test were used for comparisons between three or more
groups. The Mann-Whitney U test was used for comparison of
non-parametric data between 2 groups. Analysis of co-variance
(ANCOVA) was used when comparisons between groups required
adjustment. Mean differences with corresponding 95% confidence
intervals are also reported. CLT was not significantly different
between women who used contraceptives and those who did not,
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so we did not stratify or adjust for contraceptive use. Forward
Stepwise Multiple Regression analysis was used to determine the
main contributors to the variance in CLT in the PURE population
using parametric and log transformed data.
Results
General Characteristics of Rural and Urban Participants
Table 1 provides population characteristics for the total study
population as well as for the urban and rural groups separately.
Sex differences are also indicated for variables with sex specific
cut-offs. CLT could be determined for 1802 participants only due
to inadequate sample volume and/or haemolysis of some samples.
Baseline characteristics of the 1802 participants did not differ from
that of the total group. The mean CLT was 57.3 (611.2) minutes
(Table 1). CLT was longer in urban than in rural women (mean
difference 1.79 min, 95% CI 0.60–2.99), while no difference was
observed for men before adjustments. Taking the standard
deviation into consideration, the likelihood of this difference being
clinically significant is small. Urban participants had significantly
higher blood pressure, BMI (women only), waist circumference
(women only), triglycerides, PAI-1act and fasting blood glucose
than the rural participants. While urban women consumed more
alcohol than rural women, the opposite was seen for men.
Fibrinogen concentration and CRP were, however higher in the
rural participants.
Associations between CLT and CVD Risk Factors
The associations between CLT and various non-biochemical
cardiovascular risk factors are presented in Table 2. ANCOVA’s
were used to adjust for factors that could potentially influence/
obscure independent associations or for intermediate variables that
could, at least in part, explain the associations. These include
variables that themselves were associated with CLT and which
differed between the respective sub-categories. There was no
significant difference in CLT between different age categories,
contraceptive use or between hyper- and normotensive partici-
pants. Women had significantly longer CLTs than men (mean
difference 1.3 min 95%CI 0.27–2.38), also after adjustment for
differences in BMI and PAI-1act (which differed between men and
women, and which were associated with CLT). CLTs were
significantly increased with increasing BMI categories (mean
difference between lowest and highest BMI categories: 13.8 min,
95%CI 12.2–15.4) and in participants with abdominal obesity
(mean difference 9.3 min, 95%CI 8.31–10.3). These differences
were also likely to be clinically significant, taking the standard
deviations into consideration. Although CLT correlated with both
waist circumference (r = 0.42, p,0.0001) and BMI (r = 0.47,
p,0.0001), the correlation with BMI was stronger and BMI was
used in further analyses. Since sex differences were present
amongst the BMI and waist circumference categories, we adjusted
for sex, but significance remained. Participants who were
diagnosed with the metabolic syndrome, using the criteria
recommended by Alberti et al. [18] also had significantly longer
CLTs than those without metabolic syndrome (mean difference
4.1 min 95% CI 2.84–5.36). Current smokers had significantly
shorter CLTs than non-smokers (mean difference 4.5 min 95% CI
3.48–5.52). This significance remained after adjustment for BMI,
but disappeared after adjustment for habitual alcohol consumption
(which differed between smoking categories). Participants who
were non-drinkers had significantly longer CLTs than participants
who reported to be moderate (mean difference 5.2 min 95% CI
4.03–6.37) or heavy drinkers (mean difference 6.9 min 95% CI
5.41–8.39). Non-drinkers had significantly higher waist circum-
ference measures (also associated with longer CLT) and signifi-
cantly lower PAI-1act (associated with shorter CLTs) than drinkers,
therefore we adjusted for both, but significance remained
(p,0.0001). Men drank significantly more than women, and since
sex differences for CLT were found, we also adjusted for sex, but
again significance remained (p,0.0001).
In Table 3 associations between CLT and biochemical CVD
risk factors are presented. CLT increased significantly over HbA1c
quartiles (mean difference between lowest and highest quartiles:
8.7 min 95% CI 7.38–10.0) and fasting glucose categories (mean
difference 4.5 min 95% CI 2.97–6.03). Since a positive association
between both HbA1c and fasting plasma glucose with BMI was
found, we adjusted for BMI, but the significance between the
HbA1c quartiles and fasting glucose quartiles remained. Further-
more significantly longer CLTs were observed in participants with
increased serum triglycerides compared to normal triglyceride
levels (mean difference 7.6 min 95% CI 6.29–8.91), increased total
cholesterol levels compared to normal cholesterol (mean difference
3.5 min 95% CI 2.44–4.56) and decreased HDL-cholesterol levels
compared to the recommended values (mean difference 5.8 min
95% CI 4.70–6.90). CLT also increased significantly over the PAI-
1act (mean difference between lowest and highest quartiles
15.4 min 95% CI 14.0–16.8), fibrinogen (mean difference between
lowest and highest quartiles 4.9 min 95% CI 3.43–6.37) and CRP
quartiles (mean difference between lowest and highest quartiles
6.9 min 95% CI 5.42–8.38). Taking the standard deviation into
consideration, these differences were all likely to be clinically
significant. Significance remained for fibrinogen after adjustment
for CRP and significance also remained for CRP after adjustment
for PAI-1act and fibrinogen. CLTs tended to be longer in HIV+
compared to HIV- participants (mean difference 1.3 min 95% CI
0.11–2.49). Because there is a difference in BMI between HIV+
and HIV- participants (data not shown) and CLT correlated with
BMI we adjusted for BMI. After the adjustment, HIV+
participants now had significantly longer CLTs than the HIV-
participants (59.7 vs. 56.9 minutes).
In order to determine the main contributors to the variance of
CLT the variables in Table 2 and 3 were included in a forward
stepwise regression model. The model explained 45% of the
variance in CLT. PAI-1act explained 27% of the variance, while
BMI, alcohol consumption and HbA1c explained 8%, 3% and 2%
respectively. Triglycerides, CRP, HDL-cholesterol and HIV status
each explained only 1% of the variance. Blood pressure, total
cholesterol, fibrinogen, smoking and age each explained less than
0.5%. In order to prevent inter-correlation between the variables
BMI but not waist circumference and HbA1c but not fasting
glucose were included. Metabolic syndrome per se was also not
included as the individual components were entered into the
model separately.
Discussion
This study investigated for the first time whether urbanisation
with its resultant increased CVD risk is associated with hypofi-
brinolysis. This is also the first paper to investigate the association
between known CVD risk factors and global fibrinolytic potential
in blacks.
Rural and Urban Differences for CLT
Clot lysis time was not found to be significantly longer in the
urban than the rural participants, despite an increase in most
CVD risk factors and positive associations of these risk factors with
CLT (which will be discussed below). This can likely be explained
through the association of CLT with individual CVD risk factors.
Clot Lysis Time and CVD Risk Factors
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CVD risk factors that were increased in the urban group and that
are associated with increased clot lysis e.g. triglycerides, PAI-1 and
BMI could potentially increase CLT in the urban group. On the
other hand some CVD risk factors i.e. fibrinogen and CRP were
higher in the rural group and was also found to have positive
associations with CLT, therefore contributing to increased CLT in
the rural group. Separate analysis for men and women indicated
urban women to have a small but statistically significant longer
mean CLT than rural women, while no differences were observed
for men. A possible reason for rural-urban differences in CLT
observed in women and not in men is that the rural-urban
differences in the CVD risk factors were more pronounced in the
women than the men. This was indeed the case for BMI, for which
the rural-urban difference in women was 7 times that of the
difference in men. The relative importance of BMI in CLT was
additionally established with the multiple regression analysis.
Association of CLT with CVD Risk Factors
Of the known CVD risk factors investigated, the main
contributors to the variance in CLT in this population, as
determined with a forward stepwise multiple regression model
which included the variables in Tables 2 and 3, were PAI-1act
(27%), BMI (8%), alcohol consumption (3%) and HbA1c (2%). A
previous study conducted in a population of European descent
found triglycerides, BMI, diastolic blood pressure, systolic blood
pressure and CRP to be the main contributors to CLT, PAI-1 was,
however, not measured [8].
In a separate study investigating the main coagulation and
fibrinolytic factors associated with CLT, PAI-1ag, in agreement
with our PAI-1act results, was found to have the strongest
association, explaining 24% of CLT variation in a multiple
regression model [19]. The differences in CLT across especially
the PAI-1 and BMI quartiles may be of clinical relevance. The
Table 1. Characteristics of the South African PURE study population.
Variable Total population (n=2010) Urban (n =1004) Rural (n = 1006) Rural vs. urban p-value
Age (years) 48 (41–56) 48 (42–57) 47 (41–55) 0.0002
Men/women n (%) 749 (37.3)/1260 (62.7) 401 (39.9)/602 (60.0) 348 (34.6)/658 (65.4) 0.01
CLT (minutes) 57.3611.2 57.6612.0 57.0610.5 0.09
Men 52.9611.6* 52.6612.4* 53.3610.6* 0.55
Women 59.9610.2* 60.8610.5* 59.0610.0* 0.015
SBP (mm/Hg) 133.5624.5 137.3625.1 129.7623.3 ,0.0001
DBP (mm/Hg) 87.7614.5 89.3614.5 86.2614.5 ,0.0001
BMI (kg/m2) 22.9 (19.3–28.6) 23.4 (19.5–29.4) 22.4 (19.1–28.1) ,0.0001
Men 19.8 (18.1–22.4) 20.0 (18.3–22.8) 19.7 (18.0–22.2) 0.60
Women 25.8 (21.4–31.7) 27.1 (22.3–32.5) 24.9 (20.8–30.7) ,0.0001
Waist circumference (cm) 77.5 (70.2–87.7) 78.5 (70.9–89.0) 76.0 (69.7–86.9) 0.001
Men 74.4 (69.9–81.3)* 74.3 (69.7–81.8)* 74.5 (70.2–80.5)* 0.49
Women 81.1 (70.6–91.3)* 82.8 (73.1–92.8)* 78.8 (69.5–89.5)* ,0.0001
HDL-cholesterol (mmol/l) 1.5260.63 1.5260.65 1.5260.62 0.83
Men 1.5860.66* 1.6160.66* 1.5560.66 0.22
Women 1.4860.62* 1.4660.63* 1.5060.61 0.17
Triglycerides (mmol/l) 1.08 (0.82–1.55) 1.11 (0.84–1.65) 1.05 (0.80–1.43) ,0.001
Total cholesterol (mmol/l) 4.82 (4.01–5.87) 4.89 (4.00–5.97) 4.75 (4.02–5.80) 0.32
LDL-cholesterol (mmol/l) 2.79 (2.08–3.65) 2.81 (2.07–3.66) 2.77 (2.09–3.63) 0.95
PAI-1 (U/ml) 4.26 (1.27–7.92) 5.01 (1.76–9.11) 3.58 (0.81 6.85) ,0.0001
Fibrinogen (g/l) 2.90 (2.30–5.00) 2.70 (2.20–4.30) 3.00 (2.40–5.40) ,0.0001
Men 2.60 (2.10–3.70)* 2.50 (2.00–3.30)* 2.80 (2.20–4.30)* 0.04
Women 3.10 (2.30–5.50)* 2.90 (2.30–5.40)* 3.20 (2.50–5.70)* ,0.001
HbA1c 5.50 (5.30–5.80) 5.50 (5.20–5.80) 5.60 (5.30–5.80) 0.89
Fasting plasma glucose (mM) 4.80 (4.30–5.30) 4.90 (4.30–5.40) 4.70 (4.40–5.20) 0.06
CRP (mg/l) 3.29 (0.96–9.34) 3.25 (1.12–9.85) 3.33 (0.85–9.02) 0.07
Alcohol consumption (g/day)
(Alcohol consumers only)
Total group (n = 872) 15.4 (6.43–34.7) 15.9 (7.71–30.9) 15.0 (5.14–44.8) 0.96
Men (U n = 281, R n= 186) 19.7 (7.71–40.0)* 19.3 (11.4–34.7)* 21.9 (5.86–56.6)* 0.88
Women (U n = 252, R n = 153) 13.4 (4.29–30.9)* 14.8 (4.86–26.8)* 11.4 (3.21–38.6)* 0.92
Parametric data reported as mean 6 SD and non-parametric data as median (25th-75th percentile); SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body
mass index, HDL, high density lipoprotein; LDL, low-density lipoprotein, PAI-1, plasminogen activator inhibitor type-1; HbA1c, glycosylated haemoglobin; CLT, clot-lysis
time; R rural; U, urban; *Means differed significantly between sexes; rural vs. urban p-value adjusted for age and sex, and only for age where values are reported for men
and women separately.
doi:10.1371/journal.pone.0048881.t001
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difference between the lowest and highest quartiles were around
15 minutes while differences between arterial thrombosis patients
and controls in previous studies ranged from 1.9 to 10.8 minutes
[7,8,19].
Interestingly, in the PURE population CLT correlated better
with BMI than with waist circumference even though PAI-1act had
a significantly stronger correlation with waist circumference [20].
This stronger correlation of PAI-1 with waist circumference is
likely due to the fact that visceral adipose tissue is a major source of
PAI-1 and that its levels are further increased by hepatic
production in response to adipocyte-derived cytokines [21–24].
Adjustment for PAI-1act did not significantly affect the results and
CLT remained longer with increased BMI categories and in
individuals with abdominal obesity. While PAI-1act seems to be
Table 2. Non-biochemical cardiovascular disease risk factors and their association with CLT.
Variable N
Mean CLT (95% CI)
minutes
ANCOVA p-value: Model 1N (Model 2)D
variables adjusted for Mean difference (95% CI)
Age groups
30–39 years 332 56.9 (55.9–57.9) 0.71 0.8 (20.95–2.55)
40–49 years 700 57.5 (56.7–58.3) (0.56) Smoking, alcohol
50–59 years 482 57.0 (55.9–58.0) consumption and BMI
$60 years 288 57.7 (56.3–59.2)
Sex ,0.0001
Men 670 52.9 (52.1–53.9) (,0.0001) BMI 1.3 (0.27–2.38)
Women 1132 59.9 (59.3–60.5) (0.003) PAI-1act, BMI
Contraceptive use
Yes 403 60.5 (59.5–61.6) 0.10 1.1 (20.18–2.38)
No 667 59.4 (58.7–60.2)
Blood pressure
Normal 946 57.3 (56.6–58.0) 0.93 0 (21.05–1.05)
Hypertensive 842 57.3 (56.5–58.1)
BMI
,18.5 kg/m2 314 50.8 (49.6–52.0){ ,0.0001 13.8 (12.2–15.4)
18.5–24.9 kg/m2 739 55.3 (54.5–56.0){ (0.0001) PAI-1act
25–29.9 kg/m2 297 60.8 (59.6–61.9){ (,0.001) PAI-1act, sex
$30 kg/m2 354 64.6 (63.6–65.6){
Waist circumference ,0.0001
Normal 1168 54.1 (53.5–54.7){ (,0.0001) PAI-1act 9.3 (8.31–10.3)
Abdominal obesity 617 63.4 (62.6–64.2){ (,0.0001) PAI-1act, sex
Metabolic syndrome
Yes 434 60.4 (59.2–61.5){ ,0.0001 4.1 (2.84–5.36)
No 1358 56.3 (55.7–56.9){
Metabolic Syndrome risk score
0 278 56.4 (55.1–57.6) ,0.0001 5.5 (3.81–7.19)
1 604 54.9 (54.0–55.8)
2 476 58.0 (57.1–59.0)
$3 434 60.4 (59.2–61.5)
Smoking status
Yes 943 55.3 (54.6–56.1){ ,0.0001 4.5 (3.48–5.52)
No 785 59.8 (59.0–60.5){ (0.016) BMI
Former 66 56.0 (52.9–59.0) (0.78) BMI, alcohol
Alcohol consumption ,0.001
Non-drinkers 964 60.0 (59.4–60.7){1 ,0.0001) Sex, WC 6.9 (5.41–8.39)
Moderate drinkers* 467 54.8 (53.9–55.8){ (,0.0001) Sex, WC,
Heavy drinkers** 320 53.1 (51.7–54.4)1 PAI-1act,
*Moderate drinking: .0,15 g/day for women; .0,30 g/day for men; **Heavy drinking: $15 g/day for women; $30 g/day for men; {{1|Means with the same symbol
differed significantly; "Mean differed significantly from other means in subgroup. WC: waist circumference; BMI: Body mass index; PAI-1: Plasminogen activator inhibitor
type-1. For groups with more than two subgroups the difference between the highest and lowest value are reported. N varies among variables due to lack of sample
availability that occurred randomly during sample collection. NModel 1: adjusted for age; DModel 2: adjusted for age as well as variables indicated in table.
doi:10.1371/journal.pone.0048881.t002
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more related to central obesity, CLT seems to be related to general
obesity. Although increased PAI-1act levels likely play a major role
in this relationship, there seem to be additional mechanisms
involved in the association between body fat and CLT, unrelated
to the PAI-1 and visceral fat link.
CLT was significantly associated with both glucose and HbA1c.
In agreement with these results, Guimara˜es et al. [7] and Meltzer
et al. [6] found white diabetic subjects to have longer CLT than
non-diabetic subjects. Another study, however, found no associ-
ation between CLT and diabetes in control subjects [8]. CLT was
also longer in participants diagnosed with the metabolic syndrome,
than those without. These results are to be expected since most of
the criteria for the metabolic syndrome were all found to be
associated with longer CLTs. These results are in agreement with
the results of Carter et al. [25], who found CLT to be longer in
white patients with the metabolic syndrome, although a different
classification system was used to diagnose metabolic syndrome and
their clot lysis assay differs from the assay we used.
Although CLT was increased across fibrinogen quartiles,
fibrinogen concentration explained less than 0.5% of the variance
in CLT and correlated only weakly with CLT (r = 0.18,
p,0.0001), indicating that fibrinogen concentration was not one
Table 3. Biochemical cardiovascular disease risk factors and their association with CLT.
Variable N
Mean CLT (95% CI)
minutes





,5.3 443 53.1 (52.2–54.0){ ,0.0001 8.7 (7.38–10.0)
$5.3–,5.5 289 54.1 (52.9–55.3){ (,0.0001) BMI
$5.5–,5.8 490 57.8 (56.8–58.8)
$5.8 564 61.8 (60.9–62.8)
Fasting glucose
#5.5 mmol/l 1435 56.5 (55.9–57.0) ,0.0001 4.5 (2.97–6.03)
.5.5 mmol/l 297 61.0 (59.6–62.5) (0.003) BMI
Triglycerides
,1.7 mmol/l 1417 55.8 (55.2–56.3){ ,0.0001 7.6 (6.29–8.91)
$1.7 mmol/l 342 63.4 (62.2–64.6){
Total cholesterol
,5.2 mmol/l 1059 55.8 (55.2–56.5){ ,0.0001 3.5 (2.44–4.56)
$5.2 mmol/l 710 59.3 (58.5–60.1){
HDL-cholesterol
Men .1, women.1.2 mmol/l 1233 55.5 (54.9–56.1){ ,0.0001 5.8 (4.70–6.90)
Men,1, women,1.2 mmol/l 536 61.3 (60.4–62.2){
PAI-1act
,1.27 U/ml 456 50.2 (49.3–51.2){ ,0.0001 15.4 (14.0–16.8)
$1.27–,4.26 U/ml 460 54.9 (54.1–55.7){ (,0.0001) Sex
$4.26–,7.92 U/ml 446 58.7 (57.9–59.5){
$7.92 U/ml 440 65.6 (64.5–66.7){
Fibrinogen
,2.3 g/L 471 55.1 (54.0–56.1){| ,0.0001 4.9 (3.43–6.37)
$2.3–,2.9 g/L 380 56.3 (55.2–57.4){1 (,0.001) CRP
$2.9–,5 g/L 406 58.7 (57.6–59.8){1
$5 g/L 421 60.0 (59.0–61.0){|
CRP
,0.964 mg/L 431 53.8 (52.8–54.7){ ,0.0001 6.9 (5.42–8.38)
$0.964–,3.286 mg/L 443 56.2 (55.2–57.1){ (,0.0001) PAI-1act
$3.286–,9.340 mg/L 442 58.3 (57.3–59.4){ (,0.0001) Fibrinogen
$9.340 mg/L 445 60.7 (59.5–61.8){ (,0.0001) PAI-1act, fibrinogen
HIV status
Positive 306 58.4 (57.4–59.4){ 0.052 1.3 (0.11–2.49)
Negative 1486 57.1 (56.5–57.7){ (,0.0001) BMI
{{1|Means with the same symbol differed significantly. HDL-cholesterol: high density lipoprotein cholesterol; PAI-1: Plasminogen activator inhibitor type-1; CRP: C-
reactive protein; HbA1c: Glycosylated haemoglobin; HIV: Human Immunodeficiency Virus. For groups with more than two subgroups the difference between the
highest and lowest value are reported. N varies among variables due to lack of sample availability that occurred randomly during sample collection. NModel 1: adjusted
for age; DModel 2: adjusted for age as well as variables indicated in table.
doi:10.1371/journal.pone.0048881.t003
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of the main contributing factors of CLT variance in this
population. Theoretically fibrinogen could influence fibrin lysis
rates through its effect on clot structure as has been demonstrated
in purified models [26–28]. This effect, however, is less prominent
in plasma models likely due to the presence and interaction of
other plasma components that also affect clot lysis. It is also
possible that other factors included in the model influenced the
prediction value of fibrinogen. We also saw a significant increase
in CLT across CRP quartiles, also after adjustment for PAI-1 and
fibrinogen indicating an independent positive association between
inflammation and CLT. These results are in agreement with
associations between CLT, fibrinogen and CRP data from the
literature [5,8].
We found no association between CLT and age and between
CLT and blood pressure whereas studies in populations of
European descent found trends of increased CLT with increased
age [5,7,8] and increased systolic and diastolic blood pressure [8].
In agreement with this, no association was found between PAI-1act
and age in the PURE study population [20].
Our results also show women to have significantly longer CLTs
than men, while other studies found, although not significantly,
longer CLTs in white men than in women [5,6], or no differences
between men and women [7]. Possible factors that might have
explained the longer CLT in women in our study, are PAI-1act and
BMI, which were both found to be higher in the women than in
the men [20]. Adjustment for PAI-1act and BMI did, however, not
significantly affect the results and CLTs remained longer in
women than in men, indicating a possible real sex difference in this
study population.
We found significantly shorter CLTs for moderate and heavy
drinkers than for non-drinkers, while studies in populations of
European descent reported no apparent differences between
regular users of alcohol and participants who do not use alcohol
or do so only occasionally [7,8]. Three factors that differed
significantly between drinkers and non-drinkers [20] and that were
found to be associated with CLT were considered in order to
explain the association between CLT and alcohol consumption.
These factors were sex, waist circumference and PAI-1act [20].
Significant differences in CLT between drinkers and non-drinkers,
remained, however after separate adjustment for these three
factors. The fact that CLT is shorter in drinkers in this population,
while a main factor determining CLT, PAI-1act was found to be
increased, suggests that alcohol affects CLT at least in part, in a
PAI-1act unrelated manner.
HIV+ participants had longer CLT’s than HIV- participants
after adjustments for BMI differences. One would expect the HIV-
group, who had the higher BMI values to have longer CLTs due
to the link between PAI-1act and adipose tissue or overall body fat.
Positive HIV status has on the other hand been shown to be
associated with increased PAI-1 antigen and therefore probably
impaired fibrinolysis. This increase may be attributed to fat
redistribution in patients infected with the HIV virus [29].
However, in the PURE population PAI-1act did not differ between
the HIV+ and HIV- participants [30].
Due to the fact that many haemostatic factors play a role and/
or influence CLT, the fact that only PAI-1act and fibrinogen
concentration were measured in this study population may be a
limitation to the interpretation of the results of this study and could
potentially lead to residual confounding. Additionally, this being a
cross-sectional study, causality could not be determined for CLT.
While every attempt has been made to prevent possible selection
bias, it is not impossible that it may have occurred in some form.
In conclusion CLT in black Africans associated significantly
with many known CVD risk factors. Differences in these
associations were however observed, compared to available data
from white populations, suggesting possible ethnic differences in
the association of CLT with CVD risk. Of the variables measured,
CLT was most strongly related to PAI-1act and BMI. CLT seems
to be strongly affected by total body fat, but it seems only partly
through the PAI-1-visceral fat link. Additional research is required
to determine which factors associated with obesity influences CLT.
Alcohol consumption in this population was significantly associ-
ated with shorter CLT, despite increased PAI-1act. This also
deserves further attention. Urbanisation per se is not associated
with hypofibrinolysis despite an increase in presence of many
CVD risk factors. The effect of urbanisation on CLT is dependent
on the relationship of the individual CVD risk factors with CLT
and to which degree urbanisation affects these risk factors.
Acknowledgments
We thank the PURE-SA research team, the field-workers and office staff in
the Africa Unit for Transdisciplinary Health Research (AUTHeR), North-
West University, South Africa, and the PURE project staff at the PHRI,
Hamilton Health Sciences and McMaster University, ON, Canada.
Author Contributions
Conceived and designed the experiments: AK MP JCJ ZDL DCR.
Performed the experiments: ZDL. Analyzed the data: MP ZDL.
Contributed reagents/materials/analysis tools: MP JCJ. Wrote the paper:
ZDL MP JCJ DCR.
References
1. Yusuf S, Reddy S, Ounpuu S, Anand S (2001) Global burden of cardiovascular
diseases: Part II: variations in cardiovascular disease by specific ethnic groups
and geographic regions and prevention strategies. Circulation 104: 2855–2864.
2. Collen D, Lijnen HR (1991) Basic and clinical aspects of fibrinolysis and
thrombolysis. Blood 78: 3114–3124.
3. Gorog DA (2010) Prognostic value of plasma fibrinolysis activation markers in
cardiovascular disease. J Am Coll Cardiol 55: 2701–2709.
4. Lisman T, Leebeek FW, Mosnier LO, Bouma BN, Meijers JC, et al. (2001)
Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not
associated with increased plasma fibrinolysis. Gastroenterology 121: 131–139.
5. Lisman T, De Groot PG, Meijers J, Rosendaal FR (2005) Reduced plasma
fibrinolytic potential is a risk factor for venous thrombosis. Blood 105: 1102–
1105.
6. Meltzer ME, Lisman T, Doggen CJ, De Groot PG, Rosendaal FR (2008)
Synergistic effects of hypofibrinolysis and genetic and acquired risk factors on the
risk of a first venous thrombosis. PLoS Med 5: 751–759.
7. Guimara˜es AHC, De Bruijne ELE, Lisman T, Dippel DWJ, Deckers JW, et al.
(2009) Hypofibrinolysis is a risk factor for arterial thrombosis at young age.
Br J Haematol 145: 115–120.
8. Meltzer ME, Doggen CJM, De Groot PG, Rosendaal FR, Lisman T (2009)
Reduced plasma fibrinolytic capacity as a potential risk factor for a first
myocardial infarction in young men. Br J Haematol 145: 121–127.
9. Leander K, Blomba¨ck M, Walle´n H, He S (2012) Impaired fibrinolytic capacity
and increased fibrin formation associate with myocardial infarction. Thromb
Haemost 107: 1092–1099.
10. Siegerink B, Meltzer ME, de Groot PG, Algra A, Lisman T, et al. (2011) Clot
lysis time and the risk of myocardial infarction and ischaemic stroke in young
women; results from the RATIO case-control study. Br J Haematol 156: 252–
258.
11. Steyn K, Sliwa K, Hawken S, Commerford P, Onen C, et al. (2005) Risk factors
associated with myocardial infarction in Africa. Circulation 112: 3554–3561.
12. Pieters M, Dolman R, Ntyintyane L, Jerling J, Raal F (2011) Risk factor profile
of coronary artery disease in black South Africans. S Afr Heart J 8: 4–11.
13. Fuster V, Kelly BB (2010) Promoting cardiovascular health in the developing
world: A critical challenge to achieve global health. Washington D.C: The
National Academies Press. 484 p.
14. Vorster H (2002) The emergence of cardiovascular disease during urbanisation
of Africans. Public Health Nutr 5: 239–243.
Clot Lysis Time and CVD Risk Factors
PLOS ONE | www.plosone.org 7 November 2012 | Volume 7 | Issue 11 | e48881
15. Pieters M, de Maat MPM, Jerling JC, Hoekstra T, Kruger A (2011) Fibrinogen
concentration and its role in CVD risk in black South Africans–effect of
urbanisation. Thromb Haemost 106: 448–456.
16. Teo K, Chow CK, Vaz M, Rangarajan S, Yusuf S (2009) The Prospective
Urban Rural Epidemiology (PURE) study: Examining the impact of societal
influences on chronic non-communicable diseases in low-, middle-, and high-
income countries. Am Heart J 158: 1–7.
17. Yusuf S, Islam S, Chow CK, Rangarajan S, Dagenais G, et al. (2011) Use of
secondary prevention drugs for cardiovascular disease in the community in high-
income, middle-income, and low-income countries (the PURE Study): a
prospective epidemiological survey. Lancet 378: 1231–1243.
18. Alberti K, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, et al. (2009)
Harmonizing the metabolic syndrome. Circulation 120: 1640–1645.
19. Meltzer ME, Lisman T, de Groot PG, Meijers JCM, le Cessie S, et al. (2010)
Venous thrombosis risk associated with plasma hypofibrinolysis is explained by
elevated plasma levels of TAFI and PAI-1. Blood 116: 112–121.
20. Pieters M, de Lange Z, Hoekstra T, Ellis SM, Kruger A (2010) Triglyceride
concentration and waist circumference influence alcohol-related plasminogen
activator inhibitor-1 activity increase in black South Africans. Blood Coagul
Fibrinolysis 21: 736–743.
21. Alessi M, Peiretti F, Morange P, Henry M, Nalbone G, et al. (1997) Production
of plasminogen activator inhibitor 1 by human adipose tissue: possible link
between visceral fat accumulation and vascular disease. Diabetes 46: 860–867.
22. Bastelica D, Morange P, Berthet B, Borghi H, Lacroix O, et al. (2002) Stromal
cells are the main plasminogen activator inhibitor-1-producing cells in human
fat: Evidence of differences between visceral and subcutaneous deposits.
Arterioscler Thromb Vasc Biol 22: 173–178.
23. Alessi MC, Bastelica D, Morange P, Berthet B, Leduc I, et al. (2000)
Plasminogen activator inhibitor 1, transforming growth factor-beta1, and BMI
are closely associated in human adipose tissue during morbid obesity. Diabetes
49: 1374–1380.
24. Samad F, Yamamoto K, Loskutoff DJ (1996) Distribution and regulation of
plasminogen activator inhibitor-1 in murine adipose tissue in vivo. Induction by
tumor necrosis factor-alpha and lipopolysaccharide. J Clin Invest 97: 37–46.
25. Carter AM, Cymbalista CM, Spector TD, Grant PJ (2007) Heritability of clot
formation, morphology, and lysis. Arterioscler Thromb Vasc Biol 27: 2783–
2789.
26. Kim PY, Stewart RJ, Lipson SM, Nesheim ME (2007) The relative kinetics of
clotting and lysis provide a biochemical rationale for the correlation between
elevated fibrinogen and cardiovascular disease. J Thromb Haemost 5: 1250–
1256.
27. Falls LA, Farrell DH (1997) Resistance of gammaA/gamma’ fibrin clots to
fibrinolysis. J Biol Chem 272: 14251–14256.
28. Ryan EA, Mockros LF, Weisel JW, Lorand L (1999) Structural origins of fibrin
clot rheology. Biophys J 77: 2813–2826.
29. Hadigan C, Meigs J, Rabe J, D’agostino R, Wilson P, et al. (2001) Increased
PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-
infected patients with fat redistribution and insulin resistance. J Clin Endocrinol
Metab 86: 939–943.
30. Fourie C, Van Rooyen J, Pieters M, Conradie K, Hoekstra T, et al. (2011) Is
HIV-1 infection associated with endothelial dysfunction in a population of
African ancestry in South Africa? Cardiovasc J Africa 22: 134–140.
Clot Lysis Time and CVD Risk Factors
PLOS ONE | www.plosone.org 8 November 2012 | Volume 7 | Issue 11 | e48881
